What Is Lonapegsomatropin?

1. How does a growth hormone prodrug work?

A prodrug is a molecule that becomes active only after the body changes it. Here, a 22 kDa somatropin molecule is joined to four 10 kDa chains of methoxy-PEG through a linker, giving a 63 kDa conjugate (FDA label). The bulky carrier slows removal from the body, so a single injection can cover a week.

The linker is the TransCon part of the design. According to the developers’ 2017 review, it breaks apart on its own at the body’s normal pH and temperature, a process called autohydrolysis, without needing enzymes. Each break frees one somatropin molecule that is identical to the hormone in daily injections, while the empty carrier is cleared through the kidneys.

That sets it apart from long-acting GH products that alter the hormone itself. Somapacitan (Sogroya), for instance, is a GH analog with one amino-acid substitution plus a side chain that attaches to albumin, a common blood protein (Sogroya label). With lonapegsomatropin, the molecule acting on GH receptors is native somatropin.

Once released, the hormone behaves like any somatropin. It acts on tissues directly, for example by increasing fat breakdown and glucose output from the liver, and indirectly by raising insulin-like growth factor-1 (IGF-1), which drives bone growth in children (FDA label).

2. How long does it last, and what does the weekly curve look like?

Weekly dosing produces a rise and fall across each seven-day interval rather than daily peaks. At steady state, the label reports these values; pediatric figures are observed means and adult figures are model estimates (FDA label).

Several practical points follow from the label:

• Half-life. In children, the prodrug had a mean half-life of 30.7 hours, with wide variation (±12.7 h). Released somatropin had an apparent half-life of about 25 hours.
• No stacking up. Repeated weekly doses did not lead to significant accumulation of the prodrug or of free somatropin.
• IGF-1 timing. IGF-1 peaks roughly 2 days after an injection, and the level that best represents the weekly average falls about 4.5 days after it.
• Dose and IGF-1 in adults. Each 1 mg/week change in dose moves the weekly average IGF-1 standard deviation score (SDS, how far a value sits from the age- and sex-matched average) by about 0.7.
• Organ impairment. No studies have been done in people with kidney or liver impairment.

The earliest human data came from a first-in-human trial in 44 healthy men given one dose of lonapegsomatropin, daily somatropin or placebo. GH peaks and IGF-1 exposure were comparable to equivalent daily GH doses and rose in proportion to the dose. A half-life visualizer can sketch a decay curve, but it will not reproduce this two-step release and clearance, so the label’s measured values are the better reference.

3. What did the trials in children show?

The pivotal heiGHt trial enrolled 161 prepubertal children with GHD who had never received GH. They were randomized 2:1 to weekly lonapegsomatropin or daily somatropin, both at a total of 0.24 mg/kg per week, for 52 weeks. The study was open-label, across 73 sites in 15 countries.

The weekly product was noninferior and, on height velocity, statistically superior. Bone age advanced at a similar rate, and adverse events and antibody formation were comparable between groups. Several authors were employed by the manufacturer.

Earlier and later studies fill in the picture:

The extension studies had no comparison group. They show that growth gains held up over years, not that the weekly product outperforms daily GH over that period.

4. What did the adult trial show about fat and lean mass?

The adult indication rests on foresiGHt, which randomized 259 adults with GHD equally to weekly lonapegsomatropin, weekly placebo (both double-blind) or open-label daily somatropin, with 38 weeks of follow-up. Its primary outcome was how much trunk fat percentage changed on DXA, a low-dose X-ray body composition scan.

In the daily somatropin arm, trunk fat fell by 3.1 points and mean IGF-1 SDS ended at 0.49. The FDA label notes there was no formal statistical comparison between the weekly and daily arms, so the trial cannot say which works better for body composition.

In the 52-week open-label extension, 220 participants (88.7%) continued on the weekly drug. The body composition changes were maintained for up to 90 weeks, and 5.1% had injection site reactions. A smaller phase 2 study in 37 adults had earlier found GH and IGF-1 exposure similar to daily GH over 4 weeks, with no anti-GH antibodies.

Does this matter for muscle loss on a GLP-1?

Readers on semaglutide or tirzepatide often ask about lean mass during GLP-1 weight loss. The 1.7 kg lean mass gain above was measured in adults whose bodies lacked growth hormone. It does not show what the drug would do in someone with normal GH levels, and no study has tested lonapegsomatropin alongside a GLP-1 medicine.

5. Who is Skytrofa approved for, and how is it dosed?

The US label covers children with growth failure from inadequate GH secretion who are at least 1 year old and 11.5 kg in weight, and adults with GHD who need replacement (FDA label). It is not indicated for growth failure due to genetically confirmed Prader-Willi syndrome. The label asks for an eye exam before starting to rule out swelling of the optic disc.

In Europe, the EMA authorized the medicine in January 2022, first under the name Lonapegsomatropin Ascendis Pharma and later as Skytrofa. Its listed indication is GHD-related growth failure in children and adolescents aged 3 to 18.

The labeled starting doses are below. They are shown for reference only; actual doses are set and adjusted by the prescriber.

Oral estrogen dampens the IGF-1 response to GH, which is why those adults start higher. For people moving from daily GH, the label specifies at least 8 hours after the last daily injection before the first weekly dose; from another weekly GH product, at least 7 days. The product comes in 14 cartridge strengths from 0.7 to 13.3 mg of somatropin equivalent.

6. What are the side effects and risks?

There is no boxed warning. The warnings are those shared by all somatropin products, plus lipoatrophy (loss of fat under the skin) from repeatedly injecting the same spot (FDA label).

Lab shifts also appeared. Children were more likely than on daily GH to move to high phosphate (44.2% vs 30.2%) or high alkaline phosphatase (19.2% vs 9.4%), and adults had high alkaline phosphatase in 14% vs 6% on placebo.

Blood sugar after a weekly dose

GH reduces insulin sensitivity and can uncover impaired glucose tolerance or type 2 diabetes, so the label calls for glucose monitoring in everyone. Two pediatric case reports point to the days right after an injection. A 12-year-old with obesity and prediabetes had a blood glucose of 500 mg/dL one day after the first injection and needed insulin for a short time (Alkhatib and colleagues). A 13-year-old with obesity and hypopituitarism, without earlier glucose problems, developed diabetic ketoacidosis two days after a first dose, which resolved once GH was stopped (Mustafa and colleagues). Single cases cannot give a frequency.

Other labeled warnings and contraindications

• Critical illness. Pharmacologic somatropin raised mortality after open-heart or abdominal surgery, multiple trauma or acute respiratory failure; acute critical illness is a contraindication.
• Tumors. Active malignancy is a contraindication. Childhood cancer survivors who had head radiation face a higher risk of a second tumor, mostly meningiomas.
• Pressure in the skull. Intracranial hypertension, with headache, vision changes and vomiting, usually appears within 8 weeks and reverses when treatment stops.
• Fluid and joints. Swelling, joint and muscle aches and carpal tunnel syndrome are usually short-lived and depend on dose.
• Hormone axes. GH can lower cortisol, unmask central hypoadrenalism, and cause or worsen central hypothyroidism.
• Children. Slipped capital femoral epiphysis (a hip growth-plate injury), progressing scoliosis and pancreatitis; in children with Prader-Willi syndrome, sudden deaths on somatropin have been reported where severe obesity or breathing problems were present.
• Other contraindications. Closed growth plates in children, active proliferative or severe non-proliferative diabetic retinopathy, and hypersensitivity to the drug or its ingredients.

Antibodies and the PEG carrier

In phase 3 trials, binding antibodies appeared in 6.3% of 304 children and 5.7% of 247 adults; none neutralized the drug or were tied to side effects or reduced response (FDA label). The developers’ review notes that in animal studies, repeated dosing of PEGylated proteins has sometimes produced vacuoles, small fluid-filled spaces, in scavenger cells and kidney tubule cells, without associated organ dysfunction. That is animal data, and carcinogenicity studies of lonapegsomatropin have not been done.

There are no human pregnancy data for this product. The label notes that decades of somatropin data have not identified a drug-associated increase in birth defects or miscarriage, and that there are no data on passage into breast milk.

7. What interacts with lonapegsomatropin?

The label’s interaction section lists the following (FDA label):

GLP-1 medicines used for diabetes fall into the glucose-lowering group, but no study has looked at lonapegsomatropin together with semaglutide, tirzepatide or other incretin drugs. Anyone on both would need their prescribers to coordinate glucose monitoring.

8. Is it legal, and is it banned in sport?

In the US, Skytrofa is a prescription biologic, and its label says somatropin is not a controlled substance. A separate federal statute, which defines human growth hormone to include somatropin and its analogues, criminalizes knowing distribution of it except for an FDA-authorized use prescribed by a physician. Penalties reach 5 years in prison, or 10 if a minor is involved (21 U.S.C. 333).

The WADA 2026 Prohibited List bans growth hormone, its analogues and fragments at all times, classing them as non-Specified Substances. It lists lonapegsomatropin by name, along with the other weekly products somapacitan and somatrogon.

Outside GHD, the only human exposure is the single-dose first-in-human study in healthy men. There is no trial evidence on body composition, performance or aging in people with normal GH levels.

9. What can be measured or tracked on a weekly schedule?

Because the drug follows a weekly cycle, the timing of each measurement relative to the last injection affects how it reads. The label’s monitoring list provides the main checkpoints (FDA label):

A record that includes the injection day and site makes these results easier to interpret. Logging the date and time of each dose lets a clinician see whether an IGF-1 draw fell in the 4–5 day window, whether a high glucose reading came in the first days after a dose, and whether one injection site is being overused, which matters for lipoatrophy.

For anyone also taking a GLP-1 medicine, keeping both schedules, glucose readings, swelling and weight in one treatment log helps the prescribing team separate the effects of each drug. A log can show timing and patterns; it cannot establish which medicine caused a change.

10. Lonapegsomatropin FAQ

• Is lonapegsomatropin the same as HGH?

  It delivers the same hormone. The injected molecule is somatropin attached to a polyethylene glycol carrier, and the hormone that is released under the skin is unmodified 22 kDa somatropin, identical to the GH in daily products.

• How long does lonapegsomatropin stay in your system?

  The FDA label reports a mean half-life of about 30.7 hours for the prodrug in children and an apparent half-life of about 25 hours for the released somatropin. With weekly dosing, the label found no meaningful buildup of either from one dose to the next.

• What are the side effects of Skytrofa?

  In the pediatric trial, viral infections, fever, cough, nausea and vomiting, bleeding such as nosebleeds, and joint pain were more frequent than with daily GH. In adults, swelling and central hypothyroidism were more frequent than with placebo. Class warnings include high blood sugar, raised pressure in the skull and fluid retention.

• Is lonapegsomatropin legal?

  In the US it is a prescription biologic, and the label states that somatropin is not a controlled substance. Under a separate federal law, knowingly distributing human growth hormone or its analogues outside an FDA-authorized use prescribed by a physician is a crime.

• Can lonapegsomatropin be used with semaglutide?

  No study has tested the combination. The label says GH lowers insulin sensitivity and that doses of insulin and other glucose-lowering medicines may need adjusting, so any combination is a decision for the prescribing clinicians.

• Does Skytrofa build muscle in healthy adults?

  There is no evidence either way. The lean-mass gain in the foresiGHt trial came from replacing a missing hormone in adults with GH deficiency. No trial has given lonapegsomatropin to people with normal GH levels beyond single doses in the first-in-human study.

• Is lonapegsomatropin banned in sport?

  Yes. The WADA 2026 Prohibited List bans growth hormone and its analogues at all times and names lonapegsomatropin as an example.

• How is Skytrofa different from Sogroya?

  Skytrofa releases unmodified somatropin from a detachable carrier. Sogroya (somapacitan) is itself a modified GH molecule, with one amino-acid change and an attached side chain that binds albumin in the blood.

11. Sources